Response and Beacon will market screening tests:
This article was originally published in Clinica
Executive Summary
Response Biomedical and Beacon Diagnostics will develop, distribute and co-market the portfolio of saliva- and urine-based cancer screening tests being developed by Beacon, using Centocor tumour markers (see Clinica No 740, p 16). Beacon will use Response's Rapid Analyte Measurement Platform (RAMP) technology, which offers the possibility of point-of-care tests with the accuracy of those from laboratory-based analysers.